CAU
ZVRA icon

Caxton Associates (UK)’s Zevra Therapeutics ZVRA Stock Holding History

Caxton Associates (UK)’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1M Buy
+70,048
New +$779K 0.02% 409
2025
Q4 		– Sell
-17,317
Closed -$165K – 1003
2025
Q3 		$165K Buy
+17,317
New +$174K ﹤0.01% 650

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Caxton Associates (UK)'s ZVRA Position: Q2 2026 in Review

Caxton Associates (UK) opened a new position in Zevra Therapeutics (ZVRA) in Q2 2026: 70,048 shares worth $1M. The stake represents 0.02% of the portfolio and ranks #409 among its holdings. This is a return to the name: Caxton Associates (UK) previously reported a position in ZVRA as recently as Q3 2025.

Caxton Associates (UK) first reported a position in ZVRA in Q3 2025 and has held it in 2 quarters since. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Caxton Associates (UK) held 70,048 shares of Zevra Therapeutics worth $1M as of Q2 2026.
  • Zevra Therapeutics was a new Caxton Associates (UK) position in Q2 2026.
  • Zevra Therapeutics made up 0.02% of Caxton Associates (UK)'s portfolio in Q2 2026, its #409 holding.
  • Caxton Associates (UK) first reported a position in Zevra Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.